Your browser doesn't support javascript.
loading
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Shah, Manish A; Bennouna, Jaafar; Doi, Toshihiko; Shen, Lin; Kato, Ken; Adenis, Antoine; Mamon, Harvey J; Moehler, Markus; Fu, Xiaolong; Cho, Byoung Chul; Bordia, Sonal; Bhagia, Pooja; Shih, Chie-Schin; Desai, Anjali; Enzinger, Peter.
Afiliación
  • Shah MA; Department of Hematology & Medical Oncology, Weill Cornell Medicine, New York, NY 10021, USA.
  • Bennouna J; Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, 44000, France.
  • Doi T; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, 277-8577, Japan.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, 100142, China.
  • Kato K; Department of Head & Neck Medical Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Adenis A; Department of Medical Oncology, Institut du Cancer de Montpellier & IRCM, Inserm, Université Montpellier, ICM, Montpellier, 34298, France.
  • Mamon HJ; Department of Radiation Oncology, Brigham & Women's Hospital & Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Moehler M; Johannes Gutenberg University Clinic Mainz, Mainz, 55101, Germany.
  • Fu X; Shanghai Chest Hospital, Shanghai, 200025, China.
  • Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 120-752, South Korea.
  • Bordia S; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Bhagia P; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Shih CS; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Desai A; Department of Medical Oncology, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
  • Enzinger P; Department of Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA 02215-5450, USA.
Future Oncol ; 17(10): 1143-1153, 2021 Apr.
Article en En | MEDLINE | ID: mdl-33533655
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Protocolos Clínicos / Quimioradioterapia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Límite: Female / Humans / Male Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación / Neoplasias Esofágicas / Protocolos de Quimioterapia Combinada Antineoplásica / Protocolos Clínicos / Quimioradioterapia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Límite: Female / Humans / Male Idioma: En Revista: Future Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos